TROPION-Lung01
A TROP2 ADC helped in non-squamous lung cancer but not squamous, and the overall survival result fell short.
PFS HR 0.75 overall, driven by non-squamous (HR 0.63); OS HR 0.94 not significant. Led to a narrowed EGFR-mutant approval (TROPION-Lung05) rather than all-comers.
- Median 4.4 vs 3.7 months with Datopotamab deruxtecan compared with Docetaxel; about 0.7 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 25 percent lower chance of the event at any given time (hazard ratio 0.75, likely range 0.62 to 0.91).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- Median 12.9 vs 11.8 months with Datopotamab deruxtecan compared with Docetaxel; about 1.1 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 6 percent lower chance of the event at any given time (hazard ratio 0.94, likely range 0.78 to 1.14).
- The likely range for the hazard ratio crosses 1, so the difference could be due to chance.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- Not significant.
- Median 5.5 vs 3.6 months with Datopotamab deruxtecan compared with Docetaxel; about 1.9 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 37 percent lower chance of the event at any given time (hazard ratio 0.63, likely range 0.51 to 0.79).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Previously treated advanced NSCLC: Dato-DXd vs docetaxel. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
604 participants enrolled.
Not significant
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (BICR)primary | Datopotamab deruxtecan | 299 | 4.4 months | 0.75 (0.62–0.91) | 0.004 | link |
| Docetaxel | 305 | 3.7 months | ||||
| Overall survivalprimary | Datopotamab deruxtecan | — | 12.9 months | 0.94 (0.78–1.14) | — | link |
| Docetaxel | — | 11.8 months | ||||
| Progression-free survival, non-squamous | Datopotamab deruxtecan | — | 5.5 months | 0.63 (0.51–0.79) | — | link |
| Docetaxel | — | 3.6 months |
Pages like this
not linked directly; found by shared links- TrialHERTHENA-Lung02
Shares Benjamin Besse, Non-small-cell lung cancer.
- TrialTROPION-Breast02
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Datopotamab deruxtecan.
- TrialTROPION-Breast01
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Datopotamab deruxtecan.
- TrialTROPION-Breast05
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Datopotamab deruxtecan.
- PairingTROP2 PET → TROP2 ADC selection
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Datopotamab deruxtecan, Non-small-cell lung cancer.
- PairingCaution: TOP1 ADC immediately after TOP1 ADC
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Datopotamab deruxtecan.
- PersonSe-Hoon Lee
- PairingEGFR TKI → ADC on progression